Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.71 |
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.64 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26858991 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL15002711 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL15002884 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL26858188 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL24795598 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL24796092 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL13025155 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL34473880 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL13640857 | 1.00 | GLP1R (0.71) | GLP1RNOD1SLC6A5 | |
| SCHEMBL24788081 | 0.98 | GLP1R (0.67) | GLP1RNOD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | GLP1R 1/4885NOD1 2160/4885SLC6A5 2573/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | GLP1R 1/4885NOD1 410/4885SLC6A5 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.